ATE252899T1 - Schilddrüsenhormone enthaltende mittel - Google Patents

Schilddrüsenhormone enthaltende mittel

Info

Publication number
ATE252899T1
ATE252899T1 AT95907000T AT95907000T ATE252899T1 AT E252899 T1 ATE252899 T1 AT E252899T1 AT 95907000 T AT95907000 T AT 95907000T AT 95907000 T AT95907000 T AT 95907000T AT E252899 T1 ATE252899 T1 AT E252899T1
Authority
AT
Austria
Prior art keywords
pct
mass
agent
sec
thyroid hormone
Prior art date
Application number
AT95907000T
Other languages
English (en)
Inventor
Karrar Ahmad Khan
Alan Smith
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Application granted granted Critical
Publication of ATE252899T1 publication Critical patent/ATE252899T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95907000T 1994-02-01 1995-01-30 Schilddrüsenhormone enthaltende mittel ATE252899T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9401892A GB9401892D0 (en) 1994-02-01 1994-02-01 Therapeutic agents
PCT/EP1995/000321 WO1995020953A1 (en) 1994-02-01 1995-01-30 Therapeutic agents containing thyroid hormones

Publications (1)

Publication Number Publication Date
ATE252899T1 true ATE252899T1 (de) 2003-11-15

Family

ID=10749669

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95907000T ATE252899T1 (de) 1994-02-01 1995-01-30 Schilddrüsenhormone enthaltende mittel

Country Status (11)

Country Link
US (1) US5753254A (de)
EP (1) EP0732920B1 (de)
AT (1) ATE252899T1 (de)
AU (1) AU1537095A (de)
CA (1) CA2182038A1 (de)
DE (1) DE69532031T2 (de)
ES (1) ES2210282T3 (de)
GB (1) GB9401892D0 (de)
IL (1) IL112518A0 (de)
WO (1) WO1995020953A1 (de)
ZA (1) ZA95741B (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9611306A (pt) * 1995-11-14 1999-12-28 Knoll Pharmaceuticals Co Preparação farmacêutica e, composto farmacêutica estável.
WO1997038679A2 (en) * 1996-04-16 1997-10-23 Novartis Consumer Health S.A. Fast disintegrating oral dosage form
GB9901819D0 (en) * 1999-01-27 1999-03-17 Scherer Corp R P Pharmaceutical compositions
JP2001122785A (ja) * 1999-10-22 2001-05-08 Nippon Boehringer Ingelheim Co Ltd ブロチゾラムを含有する錠剤
US6399101B1 (en) * 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US6855333B1 (en) 2000-10-03 2005-02-15 Mutual Pharmaceutical Co., Inc. Stabilization of solid thyroid drug formulations
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6620611B2 (en) * 2001-01-06 2003-09-16 Geovation Technologies, Inc. Solid-chemical composition for sustained release of organic substrates and complex inorganic phosphates for bioremediation
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
KR20070120617A (ko) 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
JP2004525109A (ja) 2001-02-15 2004-08-19 キング・ファーマシューティカルズ・インコーポレイティッド 安定化された甲状腺ホルモン医薬組成物、及びその製法
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
WO2002066017A1 (en) * 2001-02-20 2002-08-29 Abbott Laboratories Liothyronine sodium and levothyroxine sodium combination
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030194436A1 (en) * 2001-08-10 2003-10-16 Franz Andrew G. Immediate release pharmaceutical compositions
US20030199585A1 (en) * 2001-08-10 2003-10-23 Franz G Andrew Levothyroxine compositions and methods
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
AU2002332507A1 (en) * 2001-08-10 2003-02-24 King Pharmaceuticals, Inc. Levothyroxine compositions and methods
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
WO2003028624A2 (en) * 2001-08-14 2003-04-10 King Pharmaceuticals, Inc Levothyroxine compositions and methods
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
EP1429756B1 (de) 2001-09-21 2006-11-22 Schering Corporation Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
AU2003268078A1 (en) * 2002-08-10 2004-02-25 King Pharmaceuticals, Inc. Levothyroxine compositions and methods
EP1565171A4 (de) * 2002-11-05 2010-06-30 Shire Llc Kontrollierte absorption von gemischtenschilddrüsenhormon-formulierungen
CA2504916A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
DE602004018617D1 (de) * 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
ITRM20030363A1 (it) * 2003-07-24 2005-01-25 Fernando Goglia Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
EP2428516A1 (de) * 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Neue Phosphor enthaltende Thyromimetika
WO2005067887A2 (en) * 2004-03-24 2005-07-28 Actavis Group Formulations of ramipril
RU2007148927A (ru) * 2005-05-26 2009-07-10 Метабэйзис Терапьютикс, Инк. (Us) Новые тиреомиметики, содержащие фосфиновую кислоту
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
GB0525461D0 (en) * 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
KR101865883B1 (ko) * 2011-04-08 2018-06-08 브라코 이미징 에스.피.에이. 3,5-디요오도-ｏ-[3-요오도페닐]-ｌ-티로신의 황산화 유도체의 제조 방법
EP2885005B1 (de) 2012-08-20 2017-09-27 Merck Patent GmbH Festes pharmazeutisches präparat mit levothyroxin
EP2932963A1 (de) 2014-04-16 2015-10-21 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stabile pharmazeutische Darreichungsformen enthaltend Levothyroxine Natrium
CN106267220B (zh) * 2015-05-14 2019-06-28 北京科信必成医药科技发展有限公司 愈创甘油醚氢溴酸右美沙芬无水吞服掩味制剂
CN106420625B (zh) * 2015-08-12 2021-02-26 北京科信必成医药科技发展有限公司 一种稳定的盐酸氨溴索掩味颗粒及其制备方法
CN106389339B (zh) * 2015-08-12 2020-08-04 北京科信必成医药科技发展有限公司 一种阿司匹林无水吞服掩味颗粒及其制备方法
CN109475605A (zh) * 2016-05-03 2019-03-15 斯佩特里克斯治疗有限公司 提供甲状腺激素或其类似物的组合物和方法
AU2017261225B2 (en) * 2016-05-03 2020-04-09 Spectrix Therapeutics, LLC Compositions and methods of providing thyroid hormone or analogs thereof
WO2018094265A2 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
US10231931B1 (en) 2018-03-23 2019-03-19 Genus Lifesciences Inc. Thyroid hormone oral dosage forms and methods of using the same
EP4775207A2 (de) 2018-12-05 2026-07-15 Viking Therapeutics, Inc. Zusammensetzungen zur behandlung von fibrose
EP4161925A4 (de) 2020-06-09 2024-09-04 Viking Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von lebererkrankungen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA680863A (en) * 1964-02-25 G. Ginger Leonard Compositions containing d-isomers of thyronine
US3157574A (en) * 1959-05-01 1964-11-17 Smith Kline French Lab Method of reducing cholesterol levels
US3090724A (en) * 1961-01-03 1963-05-21 Baxter Laboratories Inc Method of treating dermatological conditions
DE2126533A1 (de) * 1971-05-28 1972-12-14 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur Herstellung pharma zeutischer Zubereitungen
US4642903A (en) * 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
ES2115638T3 (es) * 1991-12-30 1998-07-01 Akzo Nobel Nv Composicion tiroactiva de liberacion controlada.

Also Published As

Publication number Publication date
DE69532031D1 (de) 2003-12-04
US5753254A (en) 1998-05-19
WO1995020953A1 (en) 1995-08-10
ZA95741B (en) 1995-08-01
IL112518A0 (en) 1995-12-08
DE69532031T2 (de) 2004-07-22
GB9401892D0 (en) 1994-03-30
AU1537095A (en) 1995-08-21
EP0732920A1 (de) 1996-09-25
EP0732920B1 (de) 2003-10-29
CA2182038A1 (en) 1995-08-10
ES2210282T3 (es) 2004-07-01

Similar Documents

Publication Publication Date Title
DE69532031D1 (de) Schilddrüsenhormone enthaltende mittel
MX9605940A (es) Compuestos bioaromaticos que llevan un grupo adamantilo en orto, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
UA42061C2 (uk) Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса
ATE522211T1 (de) Stabilisierte fibrat-mikropartikel
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
DK0893992T3 (da) Hurtigt sönderdelende oral doseringsform
ATE357216T1 (de) Fibrat-statin kombinationen mit verminderten von der nahrungsaufnahme abhängigen auswirkungen
GEP20022783B (en) Method of Preventing and Delaying Onset of Alzheimer's Disease and Composition Therefor
RU95109905A (ru) Композиции в жидком, полутвердом, твердом, гелеобразном или пастообразном виде и способ лечения заболеваний полости рта
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
FR2712807B1 (fr) Composition solide mucoadhésive, thérapeutique ou hygiénique, pour administration par application sur la muqueuse buccale ou nasale .
FR2755965B1 (fr) Composes biaromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
ES478967A1 (es) Un procedimiento para preparar compuestos de acido 3-cefem-4-carboxilico disustituido en las posiciones 3 y 7.
DE69632396D1 (de) Behandlung von erkrankungen, die vom cytokinwachstumsfaktor verursacht werden
FR2713640B1 (fr) Nouveaux composés aromatiques polycycliques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
MY124465A (en) Reduction of infarct volume using citicoline
FR2756561B1 (fr) Composes heteroaryles, compositions pharmaceutiques et cosmetiques les contenant et utilisations
FR2500303B1 (de)
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
KR960700701A (ko) 파라세타몰 및 l-시스테인 또는 이것의 전구물질을 함유하는 약제조성물(pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof)
GB9216859D0 (en) Medicaments
TNSN94110A1 (fr) Procede de preparation de compositions orales contenant des quinolones
FR2718610B1 (fr) Nouvelles formulations pesticides et leur procédé de préparation.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties